Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.
Academic Article
- Overview
- Research
- Identity
- Additional document info
- View All
Overview
publication date
- April 2019
has subject area
- Aged
- Aged, 80 and over
- Anticholesteremic Agents
- Biomarkers
- Black or African American
- Cardiovascular Diseases
- Clinical Decision-Making
- Clinical Trials as Topic
- Databases, Factual
- Dyslipidemias
- Female
- Humans
- Lipids
- Male
- Middle Aged
- PCSK9 Inhibitors
- Patient Selection
- Risk Assessment
- Risk Factors
- Serine Proteinase Inhibitors
- Time Factors
- Treatment Outcome
- United States
- White People
published in
- Cardiovascular drugs and therapy Journal